Stockscreener 앱 받기
61.10
5.07%
-3.26
시장 영업 전:
61.40
0.30
+0.49%
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - AOL.com
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - AOL.com
IRON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IRON: Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024 - TradingView
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
IRON (NASDAQ: IRON) proposed insider sales including 13,093-share 12/15/2025 sale - Stock Titan
Watertown biotech cuts 20% of staff after FDA rejects rare disease drug - The Business Journals
IRON: Wells Fargo Raises Price Target for Disc Medicine | IRON S - GuruFocus
Disc Medicine (NASDAQ:IRON) Price Target Raised to $79.00 - MarketBeat
Disc Medicine Refocuses On APOLLO Trial After FDA Letter For Bitopertin - Sahm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf RegistrationWhat's Changed - Yahoo Finance
A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings - Sahm
Disc Medicine (IRON) Announces Restructuring Following FDA Setba - GuruFocus
Disc Medicine announces workforce reduction and restructuring plan By Investing.com - Investing.com Australia
Disc Medicine announces workforce reduction and restructuring plan - Investing.com Nigeria
Insider Sell: Jean Franchi Sells Shares of Disc Medicine Inc (IR - GuruFocus
Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock - MarketBeat
Disc Medicine Implements Restructuring Following FDA Response - TipRanks
Disc Medicine's board approves restructuring plan - marketscreener.com
Disc Medicine (IRON) CFO sells 353 shares under 10b5-1 plan - Stock Titan
Disc Medicine (IRON) trims workforce 20% after FDA letter, books $2M charge - Stock Titan
Disc Medicine (NASDAQ:IRON) Price Target Lowered to $83.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results - MarketBeat
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Disc Medicine's 2025 Net Loss Widens - marketscreener.com
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Disc Medicine's 2025 net loss smaller than estimates - TradingView
Disc Medicine (NASDAQ: IRON) faces FDA CRL as hematology pipeline advances - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2025 loss, cash runway and FDA letter - Stock Titan
After FDA setback, Disc Medicine pushes rare blood drugs with $791M cash - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
Jean Franchi sells 7,081 IRON shares under 10b5-1 (IRON) - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - The Motley Fool
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients - TipRanks
Opinion | Who’s in Charge at the FDA? - WSJ
IRON SEC FilingsDisc Medicine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Shorts: Should I invest in Disc Medicine Inc before earningsPortfolio Value Summary & Free Community Consensus Stock Picks - baoquankhu1.vn
Disc Medicine, Inc. (IRON) Stock Analysis: A High-Risk, High-Reward Play with 61.59% Potential Upside - DirectorsTalk Interviews
Disc Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Disc Medicine lines up four investor events in March - Stock Titan
Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 - MarketBeat
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route - AOL.com
HC Wainwright Reduces Earnings Estimates for Disc Medicine - Defense World
Insider Selling: Disc Medicine (NASDAQ:IRON) CFO Sells $256,154.50 in Stock - MarketBeat
Jean Franchi Sells 7,081 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine CFO Sells Over 11,000 Shares - TradingView
Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question (NASDAQ:IRON) - Seeking Alpha
HC Wainwright Predicts Weaker Earnings for Disc Medicine - MarketBeat
Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program - Yahoo Finance
Disc Medicine (IRON) Projected to Post Quarterly Earnings on Thursday - MarketBeat
0.11%
6.00%
자본화:
|
볼륨(24시간):